Jump Main Menu. Go directly to the main content

Sección de idiomas

EN

Fin de la sección de idiomas

Sección de utilidades

Fin de la sección de utilidades

MENU

Events

Start of main content

Lipid Mediators: XXI century solutions for the inflammatory processes: “ From fighting the bad to promoting the good”

Life and Matter Sciences Session Thursday, November 21st, 2019, 16:30 hours Zaragoza

General information:

Venue: Paraninfo de la Universidad de Zaragoza. Plaza Basilio Paraíso 4, 50004 Zaragoza.

Free admission. Limited capacity.

In cooperation with:

Cátedra Solutex de Química Sostenible de la Universidad de Zaragoza

Coordinator/s:

Ángel Lanas

Joan Clària

  • Description
  • Programme

The inflammatory response is a host-protective mechanism against invading microbes, injuries or tissue damage such as those induced by surgery. Normally it is a self-limiting response that naturally resolves without progressing to chronic inflammation.

However, when inflammation fails to resolve it can lead to chronic inflammation with a pathophysiological nature that is associated with many prevalent diseases, such as: cardiovascular, neurodegenerative, diabetes, obesity, fatty liver, gastrointestinal inflammation, cancer, asthma, as well as the diseases with a clear inflammatory nature (i.e. arthritis, periodontitis, etc.). Nowadays we count on selective drugs where the therapeutic action mode to combat inflammation, chronic pain and tissue damage is based on the inhibition or blockade of the proinflammatory chemical mediators. Since the inflammatory response is protective, its inhibition might cause serious side effects, such as immunosuppression.

Recently, Prof. Charles Serhan at Harvard Medical School (Boston, USA) discovered that resolution of the inflammatory response is an active process that is regulated by novel genus of endogenous lipid mediators called SPMs (Specialized Proresolving Lipid Mediators). These novel bioactive mediators are enzymatically converted from the Omega 3 fatty acids EPA and DHA (Namely the Resolvins, Protectins and Maresins) and also a metabolite family derived from the Omega 6 fatty acid Arachidonic acid (ARA) called Lipoxins. These natural occurring compounds actively promote resolution of inflammation and infection, reduction of chronic pain and tissue regeneration by means of newly described mechanisms.
This First.

This First Resolution of Inflammation Conference will focus on how non-resolved chronic inflammation contributes to liver, intestinal and atherosclerotic pathologies and its role in cancer metastasis. Additionally, our focus will also include therapeutic possibilities, diagnosis and essential immunonutrition in order to shift from fighting the bad (immunosuppressive inhibition) to promoting the good (immunoresolution).

 

Thursday, November 21st

16:30 h.

Welcome

José María Medina 
Vicepresidente del Consejo Científico de la Fundación Ramón Areces.

José Antonio Mayoral 
Director de la Cátedra Solutex y Rector de la Universidad de Zaragoza. 

16:40 h.

Gastrointestinal cancer and unresolved inflammation

Ángel Lanas 
Professor of Medicine of the University of Zaragoza; Vice-Dean for Research Affairs at the Medical School of Medicine University of Zaragoza; Chairman of the Digestive Diseases Service at the University Hospital “Lozano Blesa” of Zaragoza, and Scientific Director of the Aragón Health Research Institute.

17:10 h.

Liver-intestine axis in fatty liver disease: role of intestinal inflammation

Agustín Albillos
Chairman of the Department of Gastroenterology and Hepatology at the Ramón y Cajal University Hospital, Madrid, Spain. Professor of Medicine at the University of Alcalá de Henares. Director of the Biomedical Research Network Center in Hepatic and Digestive Diseases (CIBEREHD) of the University of Alcala-Ramón y Cajal Hospital at the IRYCIS, Madrid, Spain.

17:40 h.

Resolution of inflammation: an evolving paradigm in liver disease

Joan Clària
Senior Consultant, Service of Biochemistry and Molecular Genetics, Hospital Clínic of Barcelona; Professor, Department of Biomedical Sciences, University of Barcelona; Director research group "Inflammation in liver diseases", IDIBAPS. Scientific coordinator, European Foundation for the Study of Chronic Liver Failure (EF-CLIF).

18:10 h.

Break

18:30 h.

Inflammation and its resolution in cardiovascular disease: specialized proresolving lipid mediators and therapeutic opportunities

Hildur Arnardottir   
Professor Department of Medicine, Translational Cardiology Karolinska Institut Estocolmo.

19:00 h.

Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases

Dipak Panigrahy    
Beth Israel Deaconess Medical Center; Center for Vascular Biology Research, Boston; Assistant Professor of Pathology. 

19:30 h.

Closing remarks

  • Activities related
  • Projects related
  • News related
  • Publications related

see all

End of main content